Your browser doesn't support javascript.
loading
Low plasma concentrations of apolipoprotein M are associated with disease activity and endothelial dysfunction in systemic lupus erythematosus.
Tydén, Helena; Lood, Christian; Jönsen, Andreas; Gullstrand, Birgitta; Kahn, Robin; Linge, Petrus; Kumaraswamy, Sunil B; Dahlbäck, Björn; Bengtsson, Anders A.
Afiliação
  • Tydén H; Department of Rheumatology, Clinical Sciences, Lund University, SE-22185, Lund, Sweden. helena.tyden@med.lu.se.
  • Lood C; Department of Rheumatology, Clinical Sciences, Lund University, SE-22185, Lund, Sweden.
  • Jönsen A; Department of Rheumatology, Clinical Sciences, Lund University, SE-22185, Lund, Sweden.
  • Gullstrand B; Department of Rheumatology, Clinical Sciences, Lund University, SE-22185, Lund, Sweden.
  • Kahn R; Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Linge P; Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.
  • Kumaraswamy SB; Department of Rheumatology, Clinical Sciences, Lund University, SE-22185, Lund, Sweden.
  • Dahlbäck B; Department of Translational Medicine, Lund University, 214 28, Malmö, Sweden.
  • Bengtsson AA; Department of Translational Medicine, Lund University, 214 28, Malmö, Sweden.
Arthritis Res Ther ; 21(1): 110, 2019 05 02.
Article em En | MEDLINE | ID: mdl-31046824
ABSTRACT

BACKGROUND:

Apolipoprotein M (apoM) is a 25-kDa apolipoprotein present in 5% of high-density lipoprotein (HDL) particles. It is suggested to be anti-atherogenic and to play a key role in sustaining endothelial barrier integrity. SLE patients have increased cardiovascular disease risk, and we aimed to investigate if apoM levels reflect endothelial function in SLE. Since apoM plasma levels decrease during inflammatory conditions, our aim was also to determine the impact of SLE disease activity on apoM plasma levels.

METHODS:

Plasma concentrations of apoM were measured by ELISA in two patient groups with systemic lupus erythematosus (SLE) and in 79 healthy control individuals. In patient group I (n = 84), evaluation time points were selected with the objective to include a wide range of clinical and laboratory variables reflecting disease activity which was measured as SLEDAI. In patient group II consisting of 140 consecutive patients, endothelial function was measured by a finger plethysmograph. A low Reactive Hyperemia Index (RHI) value indicates endothelial dysfunction.

RESULTS:

SLE patients had decreased levels of apoM compared to healthy controls (p < 0.01), with apoM levels correlating inversely with SLEDAI (r = - 0.31, p < 0.01) as well as with levels of CRP (r = - 0.26, p = 0.02) and positively with levels of C3 (r = 0.29, p < 0.01). ApoM levels were particularly low in patients with active disease from the kidney and skin and in patients with leukopenia or positive anti-dsDNA antibody test (p < 0.05). ApoM levels correlated with RHI values in young SLE patients (r = 0.32, p = 0.01), consistent with the important role of apoM in regulating endothelial integrity.

CONCLUSIONS:

ApoM levels may be regulated by SLE-related inflammatory processes and could be a marker of disease activity and endothelial dysfunction, in particular in young SLE patients. Further studies are needed to investigate the predictive value of apoM in the development of a cardiovascular disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Endotélio Vascular / Progressão da Doença / Apolipoproteínas M / Lúpus Eritematoso Sistêmico Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Endotélio Vascular / Progressão da Doença / Apolipoproteínas M / Lúpus Eritematoso Sistêmico Idioma: En Ano de publicação: 2019 Tipo de documento: Article